Corline Biomedical AB (CLBIO.ST)
SEK 8.76
(5.29%)
SEK 8.76
(5.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 28.38 Million SEK | 24.88% |
| 2022 | 22.72 Million SEK | 149.68% |
| 2021 | 9.1 Million SEK | -11.8% |
| 2020 | 10.32 Million SEK | 44.4% |
| 2019 | 7.14 Million SEK | 9.47% |
| 2018 | 6.52 Million SEK | 873.03% |
| 2017 | 671 Thousand SEK | -90.99% |
| 2016 | 7.45 Million SEK | 132.77% |
| 2015 | 3.2 Million SEK | -5.6% |
| 2014 | 3.39 Million SEK | -15.8% |
| 2013 | 4.02 Million SEK | -31.33% |
| 2012 | 5.86 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -4.39 Million SEK | 420.93% |
| 2024 Q1 | -1.7 Million SEK | -8023.81% |
| 2023 Q2 | 5.47 Million SEK | -35.57% |
| 2023 Q1 | 8.49 Million SEK | 19.81% |
| 2023 FY | -459 Thousand SEK | -102.02% |
| 2023 Q3 | 7.2 Million SEK | 31.53% |
| 2023 Q4 | -21 Thousand SEK | -100.29% |
| 2022 Q4 | 7.09 Million SEK | 2.16% |
| 2022 FY | 22.72 Million SEK | 149.68% |
| 2022 Q3 | 6.94 Million SEK | 30.39% |
| 2022 Q2 | 5.32 Million SEK | 58.08% |
| 2022 Q1 | 3.36 Million SEK | -7.22% |
| 2021 Q1 | 2.31 Million SEK | -47.19% |
| 2021 Q4 | 3.63 Million SEK | 138.66% |
| 2021 Q2 | 1.63 Million SEK | -29.11% |
| 2021 Q3 | 1.52 Million SEK | -7.2% |
| 2021 FY | 9.1 Million SEK | -11.8% |
| 2020 Q1 | 2.48 Million SEK | 1.14% |
| 2020 Q3 | 924 Thousand SEK | -63.51% |
| 2020 Q4 | 4.37 Million SEK | 373.81% |
| 2020 FY | 10.32 Million SEK | 44.4% |
| 2020 Q2 | 2.53 Million SEK | 1.85% |
| 2019 Q2 | 2.03 Million SEK | 50.33% |
| 2019 Q1 | 1.35 Million SEK | -79.35% |
| 2019 Q3 | 1.3 Million SEK | -35.99% |
| 2019 FY | 7.14 Million SEK | 9.47% |
| 2019 Q4 | 2.45 Million SEK | 88.79% |
| 2018 FY | 6.52 Million SEK | 873.03% |
| 2018 Q4 | 6.55 Million SEK | 2784.84% |
| 2018 Q1 | 312 Thousand SEK | 524.0% |
| 2018 Q3 | -244 Thousand SEK | -171.11% |
| 2018 Q2 | -90 Thousand SEK | -128.85% |
| 2017 FY | 671 Thousand SEK | -90.99% |
| 2017 Q2 | 726 Thousand SEK | -0.55% |
| 2017 Q3 | 77 Thousand SEK | -89.39% |
| 2017 Q4 | 50 Thousand SEK | -35.06% |
| 2017 Q1 | 730 Thousand SEK | -33.64% |
| 2016 Q2 | 2.53 Million SEK | 28.17% |
| 2016 FY | 7.45 Million SEK | 132.77% |
| 2016 Q1 | 1.98 Million SEK | 146.39% |
| 2016 Q4 | 1.1 Million SEK | -39.92% |
| 2016 Q3 | 1.83 Million SEK | -27.88% |
| 2015 Q4 | 804.01 Thousand SEK | 10.01% |
| 2015 FY | 3.2 Million SEK | -5.6% |
| 2015 Q1 | 517.7 Thousand SEK | -49.79% |
| 2015 Q2 | 1.14 Million SEK | 121.76% |
| 2015 Q3 | 730.84 Thousand SEK | -36.34% |
| 2014 Q3 | 715.58 Thousand SEK | -22.93% |
| 2014 Q4 | 1.03 Million SEK | 44.08% |
| 2014 FY | 3.39 Million SEK | -15.8% |
| 2014 Q2 | 928.52 Thousand SEK | 0.0% |
| 2013 FY | 4.02 Million SEK | -31.33% |
| 2012 FY | 5.86 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 117.662% |
| Ziccum AB (publ) | -23.28 Million SEK | 221.876% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 91.805% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 32.084% |
| Mendus AB (publ) | 28.48 Million SEK | 0.376% |
| Genovis AB (publ.) | 54 Million SEK | 47.445% |
| Intervacc AB (publ) | -13.79 Million SEK | 305.742% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -1207.232% |
| Active Biotech AB (publ) | -1.67 Million SEK | 1794.328% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | -184.854% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | -5.813% |
| Aptahem AB (publ) | 2.63 Million SEK | -978.822% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 929.582% |
| Kancera AB (publ) | -1.96 Million SEK | 1544.275% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -36757.143% |
| Fluicell AB (publ) | 1.73 Million SEK | -1532.911% |
| Saniona AB (publ) | 11.78 Million SEK | -140.896% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 654.622% |
| Biovica International AB (publ) | 6.87 Million SEK | -312.68% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 221.892% |
| AcouSort AB (publ) | 8.38 Million SEK | -238.3% |
| Xintela AB (publ) | 78 Thousand SEK | -36284.615% |
| Abliva AB (publ) | -35.66 Million SEK | 179.578% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 119.319% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -911.044% |
| OncoZenge AB (publ) | 3000.00 SEK | -945900.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 1570.466% |
| 2cureX AB (publ) | -37.48 Million SEK | 175.706% |
| CombiGene AB (publ) | -21.29 Million SEK | 233.298% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 6809.22% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 97.488% |
| Camurus AB (publ) | 1.58 Billion SEK | 98.204% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 123.123% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 182.464% |
| I-Tech AB | 27.56 Million SEK | -2.953% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 60.001% |
| Cyxone AB (publ) | 2.61 Million SEK | -986.94% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -733.97% |
| Biosergen AB | -456 Thousand SEK | 6323.684% |
| Cantargia AB (publ) | -3.45 Million SEK | 922.37% |
| NextCell Pharma AB | -43.74 Million SEK | 164.871% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 408.68% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | -152.98% |
| Nanologica AB (publ) | -76 Thousand SEK | 37442.105% |
| SynAct Pharma AB | -778 Thousand SEK | 3747.815% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 14804.663% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 319.625% |
| Lipum AB (publ) | 53 Thousand SEK | -53447.17% |
| BioInvent International AB (publ) | 71.46 Million SEK | 60.286% |
| Alzinova AB (publ) | 19.87 Million SEK | -42.8% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 21.816% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -1839.823% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 189300.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -1611.701% |
| Simris Alg AB (publ) | 2 Million SEK | -1314.051% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 892.737% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 19.803% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 2805.434% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -805.841% |